Clinical outcomes of First-line Abiraterone Acetate (AA) or Enzalutamide (E) for Metastatic Castration-Resistant Prostate Cancer (mCRPC) after Androgen Deprivation Therapy (ADT) + Docetaxel (D) or ADT alone for Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

BACKGROUND: The CHAARTED and STAMPEDE trials showed that the addition of docetaxel (D) to androgen deprivation therapy (ADT) prolonged longevity of men with metastatic hormone sensitive prostate cancer (mHSPC). However, the impact of upfront D on subsequent therapies is still unexplored. As abirater...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Genitourin Cancer
Autors principals: Francini, Edoardo, Yip, Steven, Ahmed, Shubidito, Li, Haocheng, Ardolino, Luke, Evan, Carolyn P., Kaymakcalan, Marina, Shaw, Grace K., Kantoff, Philip W., Taplin, Mary-Ellen, Alimohamed, Nimira S., Joshua, Anthony M., Heng, Daniel Y. C., Sweeney, Christopher J.
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5986287/
https://ncbi.nlm.nih.gov/pubmed/29331381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2017.12.012
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars